Details of the Metabolic Reaction (MR)

General Information of This Metabolic Reaction (MR) (ID: MR001064)
Formula Reactant Fluvastatin sodium Product 6-OH-fluvastatin
Reactant Info Product Info
Metabolic Enzyme Cytochrome P450 2C9 (CYP2C9) DME Info
Metabolic Type Oxidation - Hydroxylation
Other MR(s) Related to The Reactant of This MR
Other MR(s) That Metabolize The Reactant of This MR
MR ID Reactant Product MR Type Related Drug REF
MR001063 Fluvastatin sodium 5-hydroxyfluvastatin Oxidation - 5-Hydroxylation Fluvastatin sodium [1], [2]
MR001065 Fluvastatin sodium 5-OH-fluvastatin Oxidation - Hydroxylation Fluvastatin sodium [1], [3], [4]
MR001061 Fluvastatin sodium 6-hydroxyfluvastatin Oxidation - 6-Hydroxylation Fluvastatin sodium [5]
MR001062 Fluvastatin sodium N-Deisopropyl-fluvastatin Oxidation - N-Deisopropylation Fluvastatin sodium [1], [2]
References
1 Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
2 Roles of different CYP enzymes in the formation of specific fluvastatin metabolites by human liver microsomes. Basic Clin Pharmacol Toxicol. 2009 Nov;105(5):327-32.
3 Metabolism and transport of oxazaphosphorines and the clinical implications Drug Metab Rev. 2005;37(4):611-703. doi: 10.1080/03602530500364023.
4 Assessment of ifosfamide pharmacokinetics, toxicity, and relation to CYP3A4 activity as measured by the erythromycin breath test in patients with sarcoma Cancer. 2007 Jun 1;109(11):2315-22. doi: 10.1002/cncr.22669.
5 Diagnosis and subclassification of follicle center and mantle cell lymphomas on fine-needle aspirates: A cytologic and immunocytochemical approach based on the Revised European-American Lymphoma (REAL) classification Cancer. 1999 Aug 25;87(4):216-23.

If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.